The roles of neuregulin-1 in cardiac development, homeostasis, and disease

Biomarker Insights

Volumn 10, Issue , 2015, Pages 1-9

  Rupert, Cassady E ^a   Coulombe, Kareen L K ^a,b  

^a Brown University   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Cardiac regeneration; Cardiomyocyte; ErbB receptors; Neuregulin 1; Stem cells; Therapeutic

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; MYOSIN LIGHT CHAIN 2; MYOSIN LIGHT CHAIN 2A; NEU DIFFERENTIATION FACTOR; PLACEBO; TROPONIN T; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; CELL DIFFERENTIATION; EMBRYONIC STEM CELL; ENZYME ACTIVATION; HEART CONDUCTION; HEART DEVELOPMENT; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INJURY; HEART MUSCLE CELL; HEART OUTPUT; HEART PROTECTION; HEART STROKE VOLUME; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEAN ARTERIAL PRESSURE; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLURIPOTENT STEM CELL; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN STRUCTURE; PULMONARY ARTERY CATHETERIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ANIMALIA;

EID: 84930677534     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMIMI.S20061     Document Type: Article

References (88)

1. Falls D. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284(1):14-30.
2. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. Science. 1992;256(5060):1205-10.
3. Peles E, Bacus SS, Koski RA, et al. Isolation of the NeuHER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 1992;69(1):205-16.
4. Wen D, Peles E, Cupples R, et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell. 1992;69(3):559-72.
5. Goodearl AD, Davis JB, Mistry K, et al. Purification of multiple forms of glial growth factor. J Biol Chem. 1993;268(24):18095-102.
6. Marchionni MA, Goodearl AD, Chen MS, et al. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature. 1993;362(6418):312-8.
7. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378(6555):390-4.
8. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378(6555):394-8.
9. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in develop­ment. Nature. 1995;378(6555):386-90.
10. Mei L, Nave K-A. Neuregulin-ERBB signaling in the nervous system and neu­ropsychiatric diseases. Neuron. 2014;83(1):27-49.
11. Vasti C, Hertig CM. Neuregulin-1/erbB activities with focus on the susceptibil­ity of the heart to anthracyclines. World J Cardiol. 2014;6(7):653-62.
12. Wadugu B, Kühn B. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol. 2012;302(11):H2139-47.
13. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol. 2001;28(5 suppl 16):27-32.
14. Jiang Z, Zhou M. Neuregulin signaling and heart failure. Curr Heart Fail Rep. 2010;7(1):42-7.
15. Buonanno A, Fischbach GD. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol. 2001;11(3):287-96.
16. Yokozeki T, Wakatsuki S, Hatsuzawa K, Black RA, Wada I, Sehara-Fujisawa A. Meltrin beta (ADAM19) mediates ectodomain shedding of Neuregulin beta1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells. Genes Cells. 2007;12(3):329-43.
17. Hu X, Hicks CW, He W, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9(12):1520-5.
18. Montero JC, Yuste L, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A. Dif­ferential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci. 2000;16(5):631-48.
19. Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovascular development and disease. Circ Res. 2012;111(10):1376-85.
20. Taylor AR, Taylor SB, Koenig JI. The involvement of type II neuregulin-1 in rat visuospatial learning and memory. Neurosci Lett. 2012;531(2):131-5.
21. Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci. 2004;7(6):575-80.
22. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.
23. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 1999;447(2-3):227-31.
24. Huertas-Vazquez A, Teodorescu C, Reinier K, et al. A common missense vari­ant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac death. Heart Rhythm. 2013;10(7):994-8.
25. McBride KL, Zender GA, Fitzgerald-Butt SM, et al. Association of common variants in ERBB4 with congenital left ventricular outflow tract obstruction defects. Birth Defects Res A Clin Mol Teratol. 2011;91(3):162-8.
26. Sudol M. Neuregulin 1-activated ERBB4 as a “dedicated” receptor for the Hip­po-YAP pathway. Sci Signal. 2014;7(355):e29.
27. Reischauer S, Arnaout R, Ramadass R, Stainier DYR. Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of Erbb2 signaling as a remodeling factor of myofibril architec­ture. Circ Res. 2014;115(10):845-56.
28. Hertig CM, Kubalak SW, Wang Y, Chien KR. Synergistic roles of neuregulin-1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis. J Biol Chem. 1999;274(52):37362-9.
29. Baliga RR, Pimental DR, Zhao YY, et al. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70S6K, and MEK-MAPK-RSK. Am J Physiol Hear Circ Physiol. 1999;277(5):H2026-37.
30. Rentschler S, Zander J, Meyers K, et al. Neuregulin-1 promotes forma­tion of the murine cardiac conduction system. Proc Natl Acad Sci U S A. 2002;99(16):10464-9.
31. Wang Z, Xu G, Wu Y, et al. Neuregulin-1 enhances differentiation of cardio­myocytes from embryonic stem cells. Med Biol Eng Comput. 2009;47(1):41-8.
32. Chen M, Bi L-L, Wang Z-Q, Zhao F, Gan X-D, Wang Y-G. Time-dependent regulation of neuregulin-1β/ErbB/ERK pathways in cardiac differentiation of mouse embryonic stem cells. Mol Cell Biochem. 2013;380(1-2):67-72.
33. Patel R, Kos L. Endothelin-1 and neuregulin-1 convert embryonic cardiomyo­cytes into cells of the conduction system in the mouse. Dev Dyn. 2005;233(1):20-8.
34. Sun M, Yan X, Bian Y, Caggiano AO, Morgan JP. Improving murine embry­onic stem cell differentiation into cardiomyocytes with neuregulin-1: differential expression of microRNA. Am J Physiol Cell Physiol. 2011;301(1):C21-30.
35. Hao J, Galindo CL, Tran T-L, Sawyer DB. Neuregulin-1β induces embry­onic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors. Biochem J. 2014;458(2):335-41.
36. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neo­natal and adult ventricular myocytes. J Biol Chem. 1998;273(17):10261-9.
37. Zhu W-Z, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res. 2010;107(6):776-86.
38. Montaigne D, Hurt C, Neviere R. Mitochondria death/survival signaling path­ways in cardiotoxicity induced by anthracyclines and anticancer-targeted thera­pies. Biochem Res Int. 2012;2012:951539.
39. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molec­ular advances and pharmacologic developments in antitumor activity and cardio­toxicity. Pharmacol Rev. 2004;56(2):185-229.
40. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2014;64(9):938-45.
41. Horie T, Ono K, Nishi H, et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res. 2010;87(4):656-64.
42. Sawyer DB. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105(13):1551-4.
43. Giraud M-N, Flück M, Zuppinger C, Suter TM. Expressional reprogram­ming of survival pathways in rat cardiocytes by neuregulin-1beta. J Appl Physiol. 2005;99(1):313-22.
44. Guo Yong-fang WX. NRG-1 attenuates mitochondrial dysfunction in a rat model of heart failure. Chin Med J. 2012;125(5):807-14.
45. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459-65.
46. Pentassuglia L, Sawyer DB. ErbB/integrin signaling interactions in regula­tion of myocardial cell-cell and cell-matrix interactions. Biochim Biophys Acta. 2013;1833(4):909-16.
47. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myo­cytes. J Mol Cell Cardiol. 2006;41(2):228-35.
48. Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB. Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res. 2005;311(1):135-46.
49. Cantó C, Pich S, Paz JC, et al. Neuregulins increase mitochondrial oxida­tive capacity and insulin sensitivity in skeletal muscle cells. Diabetes. 2007;56(9):2185-93.
50. Goldshmit Y, Erlich S, Pinkas-Kramarski R. Neuregulin rescues PC12-ErbB4 cells from cell death induced by H(2)O(2). Regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase. J Biol Chem. 2001;276(49):46379-85.
51. Patel N, Barrientos A, Landgraf R. The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale. J Biol Chem. 2013;288(49):35253-65.
52. Waring CD, Vicinanza C, Papalamprou A, et al. The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation. Eur Heart J. 2012;35(39):2722-31.
53. Naqvi N, Li M, Calvert JW, et al. A proliferative burst during preadolescence establishes the final cardiomyocyte number. Cell. 2014;157(4):795-807.
54. Lemmens K, Doggen K, De Keulenaer GW. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am J Physiol Heart Circ Physiol. 2011;300(3):H931-42.
55. Okoshi K, Nakayama M, Yan X, et al. Neuregulins regulate cardiac parasym­pathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation. 2004;110(6):713-7.
56. Lemmens K, Fransen P, Sys SU, Brutsaert DL, De Keulenaer GW. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation. 2004;109(3):324-6.
57. Kuramochi Y, Lim CC, Guo X, Colucci WS, Liao R, Sawyer DB. Myocyte contractile activity modulates norepinephrine cytotoxicity and survival effects of neuregulin-1beta. Am J Physiol Cell Physiol. 2004;286(2):C222-9.
58. Noireaud J, Andriantsitohaina R. Recent insights in the paracrine modula­tion of cardiomyocyte contractility by cardiac endothelial cells. Biomed Res Int. 2014;2014:923805.
59. Hedhli N, Russell KS. Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis. Curr Hypertens Rep. 2010;12(6):411-7.
60. Kuramochi Y, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reac­tive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem. 2004;279(49):51141-7.
61. Lemmens K, Segers VFM, Demolder M, De Keulenaer GW. Role of neureg­ulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem. 2006;281(28):19469-77.
62. Kalinowski A, Plowes NJR, Huang Q, Berdejo-Izquierdo C, Russell RR, Russell KS. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J. 2010;24(7):2567-75.
63. Iivanainen E, Paatero I, Heikkinen SM, et al. Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res. 2007;313(13):2896-909.
64. Szmit S, Jank M, Maciejewski H, et al. Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. J Appl Genet. 2013;54(4):447-53.
65. Fang SJ, Wu XS, Han ZH, et al. Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mech­anism. Chin Med J (Engl). 2010;123(24):3597-604.
66. Hedhli N, Huang Q, Kalinowski A, et al. Endothelium-derived neuregulin pro­tects the heart against ischemic injury. Circulation. 2011;123(20):2254-62.
67. Xiao J, Li B, Zheng Z, et al. Therapeutic effects of neuregulin-1 gene transduc­tion in rats with myocardial infarction. Coron Artery Dis. 2012;23(7):460-8.
68. Formiga FR, Pelacho B, Garbayo E, et al. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endog­enous regeneration. J Control Release. 2014;173:132-9.
69. Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 signaling induces car­diomyocyte proliferation and repair of heart injury. Cell. 2009;138(2):257-70.
70. Gu X, Liu X, Xu D, et al. Cardiac functional improvement in rats with myocar­dial infarction by up-regulating cardiac myosin light chain kinase with neuregu­lin. Cardiovasc Res. 2010;88(2):334-43.
71. Galindo CL, Kasasbeh E, Murphy A, et al. Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure. J Am Heart Assoc. 2014;3(5):e000773.
72. Hill MF, Patel AV, Murphy A, et al. Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction. PLoS One. 2013;8(2):e55741.
73. Liu X, Gu X, Li Z, et al. Neuregulin-1/erbB-activation improves cardiac func­tion and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006;48(7):1438-47.
74. Ky B, Kimmel SE, Safa RN, et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120(4):310-7.
75. Rohrbach S, Niemann B, Silber R-E, Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated acti­vation. Basic Res Cardiol. 2005;100(3):240-9.
76. Uray IP, Connelly JH, Thomázy V, et al. Left ventricular unloading alters recep­tor tyrosine kinase expression in the failing human heart. J Hear Lung Transplant. 2002;21(7):771-82.
77. Rohrbach S, Yan X, Weinberg EO, et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis: differential expression of erbB2 and erbB4 Receptors. Circulation. 1999;100(4):407-12.
78. Li B, Zheng Z, Wei Y, et al. Therapeutic effects of neuregulin-1 in diabetic car­diomyopathy rats. Cardiovasc Diabetol. 2011;10:69.
79. Gao R. Study of efficacy on cardiac remodeling of recombinant human neuregulin-1 in stable chronic systolic heart failure patients. 2012. Home - ClinicalTrials.gov. 2015. Available at: https://clinicaltrials.gov/. Accessed February 26, 2015.
80. Gao R. Study of efficacy on NT-proBNP of recombinant human neuregulin-1 in chronic heart failure patients. Home - ClinicalTrials.gov. 2015. Available at: https://clinicaltrials.gov/. Accessed February 26, 2015.
81. Gao R. Clinical trial to evaluate the efficacy and safety of recombinant human neuregulin-1. Home - ClinicalTrials.gov. 2015. Available at: https://clinicaltri­als.gov/. Accessed February 26, 2015.
82. Mendes-Ferreira P, De Keulenaer GW, Leite-Moreira AF, Brás-Silva C. Thera­peutic potential of neuregulin-1 in cardiovascular disease. Drug Discov Today. 2013;18(17-8):836-42.
83. Gao R, Zhang J, Cheng L, et al. A Phase II, randomized, double-blind, multi­center, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55(18):1907-14.
84. Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recom­binant human neuregulin-1 to patients with stable chronic heart failure pro­duces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13(1):83-92.
85. Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signal­ing. Proc Natl Acad Sci U S A. 2012;109(27):E1848-57.
86. Burridge PW, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11(8):855-60.
87. Laflamme MA, Murry CE. Heart regeneration. Nature. 2011;473(7347):326-35.
88. Home - ClinicalTrials.gov. 2015. Available at: https://clinicaltrials.gov/. Accessed February 26, 2015.